Emily Carter analyzes regulatory, policy, and governance issues influencing biotechnology and medical innovation. Her work examines how regulatory decisions, legal frameworks, and public policy shape research, commercialization, and patient access. At The Catalyst Brief, Emily brings a systems-level perspective, linking policy developments with scientific and market realities.
144 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Biopharmaceutical IndustryNovo Nordisk, a leader in obesity drug development, initiated legal proceedings against wellness platform Hims & Hers for producing and selling an unauthorized, compounded version of its oral Wegovy pill. This dispute spotlights ongoing tensions in the pharmaceutical industry around patent rights, drug compounding, and market competition.
Emily CarterFeb 9, 2026
Regulatory & PolicyRecent legislative and regulatory actions mark important steps in reforming pharmacy benefit management practices, crucial for employers managing prescription drug benefits. However, despite initial celebrations, the reforms fall short of addressing all employer concerns, notably failing to ban spread pricing, signaling that challenges remain in navigating the evolving PBM landscape.
Emily CarterFeb 8, 2026
Regulatory & PolicyThe decision to discontinue the 340B rebate pilot program comes as providers voiced concerns over the financial and administrative burdens it would impose, potentially jeopardizing essential safety-net care. This regulatory development underscores the ongoing negotiation between policy objectives and practical provider realities in the healthcare system.
Emily CarterFeb 7, 2026
Biopharmaceutical IndustryAfter decades of established pharmaceutical manufacturing on the island, Puerto Rico struggles with outdated tax frameworks but is capitalizing on geopolitical factors to entice major biopharma players like Amgen and Lilly to reengage and strengthen its sector.
Emily CarterFeb 3, 2026
Regulatory & PolicyPharmaceutical companies face growing pressure to openly disclose drug pricing decisions and rebate structures. This shift towards transparency is driven by calls for credibility and fairness in an industry historically opaque about costs, affecting stakeholder trust and regulatory scrutiny.
Emily CarterFeb 2, 2026
Regulatory & PolicyThe recent draft guidance from the U.S. Food and Drug Administration on multiple myeloma demonstrates significant progress in understanding this complex cancer. It takes into account advancements in diagnostic tools and altered patient care journeys shaped by better therapies, underscoring ongoing efforts to streamline clinical development and regulatory evaluation in this field.
Emily CarterJan 31, 2026
Regulatory & PolicyThe Senate's inability to pass a comprehensive spending package has placed the rare pediatric disease priority review voucher program in limbo, as the bill also encompasses controversial funding for federal immigration enforcement. This regulatory challenge highlights the complexities of healthcare policy-making interwoven with broader political debates and raises questions about future support for rare disease initiatives.
Emily CarterJan 30, 2026
Biopharmaceutical IndustryIn 2025, Sanofi recorded another dip in its vaccine sales, underscoring the persistent challenges faced by vaccine manufacturers in the current market environment. Although almost all immunization products saw declines, CEO Paul Hudson reaffirmed the company's commitment to vaccine innovation and its role in public health.
Emily CarterJan 29, 2026
Healthcare InvestmentWith growing awareness about the importance of lung health amid environmental challenges and respiratory concerns, Climatic's innovative inhalant product aims to establish a new category in preventive lung care. The company's recent funding underscores investor confidence in lung wellness solutions targeting proactive daily use.
Emily CarterJan 29, 2026
Regulatory & PolicyIn early 2026, a major strike by Kaiser Permanente’s healthcare workforce has brought attention to persistent challenges in the healthcare system, including staffing shortages and the struggle to balance patient care with sustainable working conditions. This detailed analysis explores the background, causes, and potential implications of the strike for the healthcare sector.
Emily CarterJan 24, 2026
Healthcare InvestmentThe significant capital infusion will fuel Corxel’s efforts to push CX11 through mid-stage development in the United States and prepare for pivotal Phase III clinical trials, underscoring investor confidence in oral GLP-1 therapies.
Emily CarterJan 23, 2026
Regulatory & PolicyThe removal of Ash, a therapy chatbot developed by Slingshot AI, from the UK market highlights the increasing scrutiny and regulatory challenges faced by digital therapeutic tools. This article analyzes the regulatory environment, the implications for digital mental health products, and the broader context of AI-driven therapies.
Emily CarterJan 21, 2026